NeoGenomics, Inc. (NEO) — Stock Score Summary

NeoGenomics, Inc. (NEO) has a MoatMap StockRank of 42/100 based on Quality (45/100), Value (31/100), and Momentum (53/100) factor scores. The current signal is HOLD. NeoGenomics is undergoing a complex operational turnaround with inconsistent profitability, failing the Terry Smith rule of avoiding broken business models hoping for a rescue.

NeoGenomics, Inc. is a leading oncology-focused diagnostics company, providing comprehensive cancer testing and information services to pathologists, oncologists, hospitals, and pharmaceutical companies. The company benefits from a broad portfolio of advanced oncology diagnostic tests, coupled with specialized expertise and a nationwide presence. NeoGenomics is a prominent player in precision oncology, offering critical diagnostic and prognostic insights that guide treatment decisions and support drug development.

Key Financial Metrics

Price$11.12
Market Cap$1.3B
P/E (Forward)31.02
Price/Book1.74
Return on Equity-11.6%
Return on Invested Capital-8.4%
Debt/Equity49.29
Gross Margin43.1%
Operating Margin-9.3%
Revenue Growth11.1%
Free Cash Flow$33M

NeoGenomics, Inc. operates in the Diagnostics & Research industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is NeoGenomics, Inc.’s (NEO) StockRank?
MoatMap’s StockRank for NeoGenomics, Inc. (NEO) is 42/100, with a Hold signal. It is a composite of Quality (45), Value (31), and Momentum (53) factor ranks across MoatMap’s 19,000+ stock universe.
Does NeoGenomics, Inc. have an economic moat?
NeoGenomics, Inc. (NEO) has a Quality factor score of 45/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is NeoGenomics, Inc. a buy, hold, or sell?
MoatMap’s current signal for NeoGenomics, Inc. (NEO) is Hold, based on a StockRank of 42/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is NeoGenomics, Inc. in?
NeoGenomics, Inc. (NEO) operates in the Healthcare sector, specifically the Diagnostics & Research industry (United States).
Browse all ranked stocksNEO deep dive reportAI ChampionsHow we score stocksSense-check another stock